Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

A new study shows that oral arginine, a naturally occurring amino acid, can significantly suppress amyloid-β aggregation in Alzheimer’s disease models.

AD is a progressive, relentless disease with Aß and tau as hallmarks. It is caused by a continuous underlying neurotoxic process driven by PF that begins before amyloid plaque accumulation and ...

Current antibody-based treatments for Alzheimer’s disease remain costly and carry significant side effects, highlighting the need for safer alternatives. In a new study, researchers from Kindai ...

Longevity expert Dr Vassily debunks the myth that arterial plaque can’t be reversed - and reveals a targeted strategy that may help reduce buildup. If you’ve always assumed that once plaque settles ...

Disrupting the chemical messages that oral bacteria use to coordinate growth may help prevent disease by keeping plaque ...

A new study finds that taking arginine orally may lower amyloid buildup and neuroinflammation, suggesting a safe, low-cost ...

Both microtubule-binding protein tau and RNA-binding protein TDP-43 have been associated with neurodegenerative diseases, such as Alzheimer’s disease, including in co-pathological deposition with each ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with Alzheimer's disease (AD) and other ...